Gut HealthNCT07264465
A Clinical Trial to Evaluate the Effects of a Chickpea Pasta on Gut Health, Blood Glucose, and Overall Health
A study testing Chickpea Pasta in people with Gut Health and Gastrointestinal Health, run by Banza LLC at 1 site in United States.
Trial summary
This is a single-arm, 12-week pilot study evaluating the effects of a chickpea pasta on gut microbiome diversity, gastrointestinal health, and blood biomarkers. The study will involve 12 participants consuming the test product five times per week, with questionnaires, microbiome testing, blood testing, and waist… Read more about this study
- Who is it for?
- Ages 21 to 44 yearsHealthy volunteers can take part
- Conditions the study is for
- Gut Health, Gastrointestinal Health
- What is being tested?
- Chickpea Pasta
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Feb 2025to 30 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 44 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Be male or female
- Be aged 21-44.
- Anyone currently experiencing issues regarding all of the following:
- Struggling to balance taste with health and convenience.
- Struggling to eat healthy due to a busy lifestyle.
- Self-reported poor gut health (including bloating, abdominal discomfort, and gas).
Show all 14Show fewer
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
- If taking oral over-the-counter supplements or herbal remedies targeted at gut health, blood sugar, and overall health and well-being, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration.
- Not planning on introducing any products or any new forms of prescription medication or supplements that target gut health, blood sugar, or overall health and well-being for the study duration.
- Anyone willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial.
- Anyone who has tried pasta alternatives in the past (e.g., made of chickpeas, lentils, beans, etc.) or, if not, is open to trying them.
- Anyone with access to a 3-quart pasta pot that can be used 5 times weekly.
- Resides in the United States.
- Not currently partaking in another research study and will not be partaking in any other research study for the next 12 weeks and at any point during this study's duration.
Who cannot join
- Has been diagnosed with Type 1 or Type 2 diabetes.
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone with known severe allergic reactions.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
- Anyone unwilling to follow the study protocol.
Show all 12Show fewer
- Anyone who has undergone any surgeries or invasive treatments in the last six months.
- Anyone planning to undergo any surgeries or invasive treatments during the study period.
- Anyone with a known history of severe digestive disorders like acid reflux, irritable bowel syndrome (IBS), irritable bowel disease (IBD), Crohn's disease, or gastrointestinal tract surgeries.
- Anyone with a history of substance abuse.
- Anyone who eats a pasta alternative (like chickpea pasta) one or more times per week.
- Follows a specific diet, such as ketogenic, paleo, or gluten-free
Trial locations and contacts
1 site in 1 country.
About this study
This is a single-arm, 12-week pilot study evaluating the effects of a chickpea pasta on gut microbiome diversity, gastrointestinal health, and blood biomarkers. The study will involve 12 participants consuming the test product five times per week, with questionnaires, microbiome testing, blood testing, and waist measurements collected at defined timepoints.
- Conditions
- Gut Health, Gastrointestinal Health
- Being tested
- Chickpea Pasta
- Keywords
- Microbiome Diversity, Nutritional Supplement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chickpea PastaDietary supplement
The intervention is intended to assess the effects of a high-fiber, legume-based dietary product on gut microbiome diversity, gastrointestinal function, and metabolic biomarkers.
| Study group | Role | What they receive |
|---|---|---|
| Chickpea Pasta Intervention Arm | Experimental | Participants will consume 1½ cups (188g) of cooked Banza chickpea pasta once daily, 5 days per week, for 12 weeks. Receives: Dietary Supplement: Chickpea Pasta |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in gut microbiome diversity
Gut microbiome diversity will be assessed using microbiome testing of stool samples. This outcome will evaluate the effect of the intervention on microbial community richness and composition.
Measured: Baseline and Week 12
Change in gastrointestinal symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
Assessed using the GSRS to evaluate symptoms such as bloating and abdominal discomfort.
Measured: Baseline, Week 4, Week 8, and Week 12
Change in blood biomarkers regarding Hemoglobin A1C
Measured via blood tests including Hemoglobin A1C with eAG.
Measured: Baseline and Week 12
Change in blood biomarkers regarding CMP-14
Measured via blood tests including CMP-14, lipid panel, and serum iron to assess metabolic and cardiovascular health indicators.
Measured: Baseline and Week 12
Change in stool quality using the Bristol Stool Scale (BSS)
Assessed using the BSS to evaluate stool consistency and form.
Measured: Baseline, Week 4, Week 8, and Week 12
Secondary outcomes (2)
Participant-reported perceptions of gut and overall health
Evaluated through self-reported questionnaires on perceived gut health, weight management, bloating, confidence in clothes, and overall well-being.
Measured: Baseline, Week 4, Week 8, and Week 12
Change in waist circumference
Participants will self-measure and report waist circumference to assess changes in central adiposity over the course of the intervention.
Measured: Baseline, Week 4, Week 8, and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2025
- Study start20 Feb 2025
- Primary completion30 Jul 2025
- Study completion30 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gut HealthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Banza LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07264465
- Sponsor's protocol ID
- 20724
- Status last verified
- Dec 2025
- First submitted
- 30 Sep 2025
- Last updated
- 4 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of a Chickpea Pasta on Gut Health, Blood Glucose, and Overall Health
- ClinicalTrials.gov ID
- NCT07264465
- Acronym / sponsor ID
- 20724
- Conditions
- Gut Health, Gastrointestinal Health
- Keywords
- Microbiome Diversity, Nutritional Supplement
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Banza LLCIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 20 Feb 2025 (actual)
- Primary completion
- 30 Jul 2025 (actual)
- Study completion
- 30 Jul 2025 (actual)
- First posted
- 4 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-arm, 12-week pilot study evaluating the effects of a chickpea pasta on gut microbiome diversity, gastrointestinal health, and blood biomarkers. The study will involve 12 participants consuming the test product five times per week, with questionnaires, microbiome testing, blood testing, and waist measurements collected at defined timepoints.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Chickpea Pasta Intervention Arm | Experimental | Dietary Supplement: Chickpea PastaParticipants will consume 1½ cups (188g) of cooked Banza chickpea pasta once daily, 5 days per week, for 12 weeks. |
Who may qualify
- Ages
- 21 to 44 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (14 listed)
- Be male or female
- Be aged 21-44.
- Anyone currently experiencing issues regarding all of the following:
- Struggling to balance taste with health and convenience.
- Struggling to eat healthy due to a busy lifestyle.
Key exclusion criteria (12 listed)
- Has been diagnosed with Type 1 or Type 2 diabetes.
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone with known severe allergic reactions.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chickpea PastaThe intervention is intended to assess the effects of a high-fiber, legume-based dietary product on gut microbiome diversity, gastrointestinal function, and metabolic biomarkers. | Dietary supplement | Chickpea Pasta Intervention Arm |
Primary outcome
Change in gut microbiome diversity
Time frame: Baseline and Week 12
Gut microbiome diversity will be assessed using microbiome testing of stool samples. This outcome will evaluate the effect of the intervention on microbial community richness and composition.
Change in gastrointestinal symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
Time frame: Baseline, Week 4, Week 8, and Week 12
Assessed using the GSRS to evaluate symptoms such as bloating and abdominal discomfort.
Change in blood biomarkers regarding Hemoglobin A1C
Time frame: Baseline and Week 12
Measured via blood tests including Hemoglobin A1C with eAG.
Change in blood biomarkers regarding CMP-14
Time frame: Baseline and Week 12
Measured via blood tests including CMP-14, lipid panel, and serum iron to assess metabolic and cardiovascular health indicators.
Change in stool quality using the Bristol Stool Scale (BSS)
Time frame: Baseline, Week 4, Week 8, and Week 12
Assessed using the BSS to evaluate stool consistency and form.
2 secondary outcomes
Participant-reported perceptions of gut and overall health
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in waist circumference
Time frame: Baseline, Week 4, Week 8, and Week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2025.
Related trials for Gut Health
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Active, not recruitingObservational study
Study on the Impact of Different Feeding Methods on Allergy Prevention and Digestive Absorption in Infants and Young Children
Infant Allergy, Infant Gut Health
Recruiting
The Impact of Overnight Active Temperature Regulation on the Gut Microbiome, Inflammation, and Circadian Rhythm.
Poor Sleep Quality, Gut Microbiome
Not yet recruiting
Exploration of Tolerability and Dose Responses for a Yeast-based Probiotic
Healthy Adult Participants, Gut Health
Recruiting
IgG Binding Protein LT in Support of a Healthy Gut on the Go
Gut Health, Gastrointestinal Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Chickpea Pasta in people with Gut Health and Gastrointestinal Health, run by Banza LLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in gut microbiome diversity (time frame: Baseline and Week 12). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025; AzTrials last refreshed its copy on 7 Nov 2026.